A House committee in Alaska has advanced a bill that would create a state task force to study how to license and regulate psychedelic-assisted therapy—a plan supporters say will help prepare the state for federal approval of substances such as MDMA and psilocybin.
At a hearing Tuesday, members of the House Military and Veterans Affairs Committee agreed to advance the measure with individual recommendations.
If it becomes law, the proposal, HB 228, would not itself change the legal status of any drugs. Rather, it would create a legislative task force that would spend the rest of 2024 studying how to license and regulate psychedelic therapy in Alaska. A report from the group with recommendations would be due on or before December 31, 2024.
Both MDMA and psilocybin have been granted breakthrough therapy status by the Food and Drug Administration (FDA), and recent clinical trials have MDMA on pace for possible FDA approval later this year.
Before advancing the bill, members of the House panel adopted amendments to bring the bill into alignment with its Senate companion, SB 166, which has already passed out of one committee in that chamber and had another committee hearing late last month.
Sponsors filed the legislation in
Read full article on Marijuana Moment
